2022 ICD-10-CM Code C55
Malignant neoplasm of uterus, part unspecified
Valid for Submission
| ICD-10: | C55 |
| Short Description: | Malignant neoplasm of uterus, part unspecified |
| Long Description: | Malignant neoplasm of uterus, part unspecified |
Code Classification
C55 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of uterus, part unspecified. The code C55 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C55 might also be used to specify conditions or terms like adenocarcinoma of uterus, adenosarcoma of uterus, carcinoma of uterus, carcinosarcoma of uterus, gestational trophoblast tnm finding , gestational trophoblast tnm finding, etc.
The code C55 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: uterus, uteri, uterine .
Unspecified diagnosis codes like C55 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
- Diagnoses for females only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to FEMALES only .
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Adenocarcinoma of uterus
- Adenosarcoma of uterus
- Carcinoma of uterus
- Carcinosarcoma of uterus
- Gestational trophoblast TNM finding
- Gestational trophoblast TNM finding
- Leiomyosarcoma of uterus
- Malignant neoplasm of uterus
- Malignant tumor involving an organ by direct extension from uterus
- Malignant tumor involving an organ by separate metastasis from uterus
- Malignant tumor involving bladder by direct extension from uterus
- Malignant tumor involving bladder by separate metastasis from uterus
- Malignant tumor involving left fallopian tube by direct extension from uterus
- Malignant tumor involving left fallopian tube by separate metastasis from uterus
- Malignant tumor involving left ovary by direct extension from uterus
- Malignant tumor involving left ovary by separate metastasis uterus
- Malignant tumor involving rectum by direct extension from uterus
- Malignant tumor involving rectum by separate metastasis from uterus
- Malignant tumor involving right fallopian tube by direct extension from uterus
- Malignant tumor involving right fallopian tube by separate metastasis from uterus
- Malignant tumor involving right ovary by direct extension from uterus
- Malignant tumor involving right ovary by separate metastasis from uterus
- Malignant tumor involving vagina by direct extension from uterus
- Malignant tumor involving vagina by separate metastasis from uterus
- Malignant tumor involving vulva by direct extension from uterus
- Malignant tumor involving vulva by separate metastasis from uterus
- Metastasis from malignant tumor of uterus
- Primary malignant neoplasm of uterus
- Primary myosarcoma of uterus
- pT1
- pT2
- Sarcoma of uterus
- Secondary malignant neoplasm of left fallopian tube
- Secondary malignant neoplasm of left ovary
- Secondary malignant neoplasm of rectum
- Secondary malignant neoplasm of right fallopian tube
- Secondary malignant neoplasm of right ovary
- Secondary malignant neoplasm of vagina
- Secondary malignant neoplasm of vulva
- T1 : Trophoblastic disease confined to uterus
- T1 : Trophoblastic disease confined to uterus with no risk factors
- T1 : Trophoblastic disease confined to uterus with one risk factor
- T1 : Trophoblastic disease confined to uterus with two risk factors
- T2
- T2 : Trophoblast: GTT extends outside of the uterus but limited to genital structures with one risk factor
- T2 : Trophoblast: GTT extends outside of the uterus but limited to genital structures with two risk factors
- T2 : Trophoblast: GTT involving genital structure without risk factors
Diagnostic Related Groups - MS-DRG Mapping
The ICD-10 code C55 is grouped in the following groups for version MS-DRG V39.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). applicable from 10/01/2021 through 09/30/2022.
| MS-DRG | MS-DRG Title | MCD | Relative Weight |
|---|---|---|---|
| 736 | UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC | 13 | 4.2582 |
| 737 | UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC | 13 | 2.0582 |
| 738 | UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC | 13 | 1.4766 |
| 739 | UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC | 13 | 3.8217 |
| 740 | UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC | 13 | 1.8 |
| 741 | UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC | 13 | 1.2795 |
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C55 to ICD-9 Code
- 179 - Malig neopl uterus NOS
Table of Neoplasms
The code C55 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
| Neoplasm, neoplastic | Malignant Primary |
Malignant Secondary |
CaInSitu | Benign | Uncertain Behavior |
Unspecified Behavior |
|---|---|---|---|---|---|---|
| »uterus, uteri, uterine | C55 | C79.82 | D07.0 | D26.9 | D39.0 | D49.59 |
Information for Patients
Uterine Cancer
The uterus, or womb, is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type is also called endometrial cancer.
The symptoms of uterine cancer include
- Abnormal vaginal bleeding or discharge
- Trouble urinating
- Pelvic pain
- Pain during intercourse
Uterine cancer usually happens after menopause. It is more common in women who have obesity. You also have a higher risk if you took estrogen-only hormone replacement therapy (menopausal hormone therapy) for many years.
Tests to find uterine cancer include a pelvic exam, imaging tests, and a biopsy. The most common treatment is a hysterectomy, which is surgery to remove the uterus. Sometimes the surgery also removes the ovaries and fallopian tubes. Other treatments include hormone therapy, radiation therapy, and chemotherapy. Some women get more than one type of treatment.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Code History
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)